Skip to Main Content

Paper Details

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
J Immunother Cancer
18
2020
), CD8, Esophageal squamous cell carcinoma, HLA, HLA class I molecules, Human, Human Leukocyte Antigen, IIIc and IV, NY-ESO-1, NY-ESO-1-specific CD4+ and CD8, Participants, melanoma, participants, tumor
Author NameAffiliation
Jonathan CebonOlivia Newton-John Cancer Research Institute, La Trobe University at Austin Health
Jonathan CebonLudwig Institute for Cancer Research Austin Branch
Grant A McArthurPeter MacCallum Cancer Centre
Grant A McArthurPeter MacCallum Cancer Centre
Cyril FisherRoyal Marsden Hospital NHS Trust
Peter HerseyCentenary Institute
Lloyd J OldLudwig Institute for Cancer Research
  • 1 - 7

Datasets

Release 1.2